Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | GMPS | P49915 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 8/20 | 0.48 |
| ▸ | MAOA | P21397 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3660250 | 0.83 | APP (0.50) | APPGMPSMAOBMAOA | |
| SCHEMBL3660168 | 0.82 | APP (0.49) | APPMAOBMAOACA12CA9 | |
| SCHEMBL3659653 | 0.81 | APP (0.51) | APPGMPSMAPTTP53 | |
| SCHEMBL13338101 | 0.81 | MAOB (0.59) | GMPSMAOBMAOAGSTP1CA12 | |
| SCHEMBL3661152 | 0.81 | APP (0.48) | APPMAOBMAOACA12CA9 | |
| SCHEMBL3663859 | 0.80 | APP (0.50) | APPGMPSMAPTMTNR1ATP53 | |
| SCHEMBL16363804 | 0.80 | SMN1; SMN2 (0.60) | GMPSMAOBMAOAMAPTEGFR | |
| SCHEMBL3663588 | 0.80 | APP (0.47) | APPMAOBMAOA | |
| SCHEMBL3660450 | 0.80 | APP (0.47) | APPMAOBMAOA | |
| SCHEMBL8306841 | 0.78 | APP (0.58) | APPTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311790-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | SUMITOMO CHIEMCAL COMPANY LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2215062-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | Sumitomo Chemical Company, Limited (JP) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009069792-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311790-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | ATL3, NAT1, C5 | APP 2380/4885GMPS 2911/4885MAOB 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.